Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Therapy for R/R Hematological Malignancies
NCT06647329Phase 1Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LV20.19 CAR-T in B cell acute lymphoblastic leukemia (B-ALL), B cell lymphoma and multiple myeloma (MM). Primary endpoint: Objective Response Rate at 6 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
LV20.19 CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B cell lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06647329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647329.